Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    YFK

No quotes available
-- EUR   0.00%
05/20 3SBIO INC. : (01530) withdraws breast cancer drug application
03/04 3SBIO : Bought CNY3.9bn Shares in CPGJ
03/04 3SBIO : adds stake in CP Guojian Pharma at Rmb3.9bn
 SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2016 2 717 M
EBIT 2016 920 M
Net income 2016 783 M
Debt 2016 852 M
Yield 2016 0,19%
Sales 2017 3 409 M
EBIT 2017 1 155 M
Net income 2017 991 M
Debt 2017 83,0 M
Yield 2017 0,10%
P/E ratio 2016 21,77
P/E ratio 2017 16,78
EV / Sales 2016 6,61x
EV / Sales 2017 5,04x
Capitalization 17 111 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
08/09Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
05/20 3SBIO INC. : (01530) withdraws breast cancer drug application
03/17 3SBIO : PEG-irinotecan Wins IND Approval From China FDA
03/04 3SBIO : Bought CNY3.9bn Shares in CPGJ
03/04 3SBIO : adds stake in CP Guojian Pharma at Rmb3.9bn
02/23 3SBIO : Wins Financing for Further Equity Investment
02/23 3SBIO : inks Rmb2.2bn term loan facility
01/27 3SBIO : to add stake in CP Guojian Pharmaceutical
01/20 3SBIO : to add stake in CP Guojian
More news
Sector news : Biopharmaceuticals
07:16a NOVARTIS : Sandoz' biosimilar rituximab regulatory submission accepted by Europe..
06:21a ONO PHARMACEUTICAL : Two-Year Overall Survival Data from Two Pivotal Opdivo® (ni..
06:21a ONO PHARMACEUTICAL : Announces Results from Phase 1/2 and Phase 3 Clinical Studi..
More sector news : Biopharmaceuticals
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions